21-10-2011: Mesoblast Limited and its strategic alliance partner Cephalon Inc. were awarded the Licensing Executives Society (U.S.A. and Canada), Inc. 2011 Deals of Distinction™ Award. The award was conferred for the most compelling licensing and intellectual property-related deal in the life sciences sector.
The citation from the Licensing Executives Society stated: “The Life Science Sector Deal of Distinction™ Award went to Cephalon and Mesoblast for their strategic alliance to develop and commercialize novel adult mesenchymal precursor stem cell therapeutics for degenerative conditions in the cardiovascular and central nervous systems. The deal was in large part driven by very impressive Phase II results obtained by Mesoblast from trials of its proprietary product Revascor™ for the treatment of congestive heart failure.
“What made the Cephalon/Mesoblast deal really stand out was the overall size of the deal and the fact that it was in the relatively "young" therapeutic area of stem cells/regenerative medicine,” said Life Science Sector Chair Michael Samardzija. The deal is said to be the largest ever in the regenerative medicine sector.
The financial aspects of this deal are impressive, including an upfront payment from Cephalon to Mesoblast totalling $130 million, obligations to fund Phase llb and Phase 3 trials, regulatory milestone payments of up to $1.7 billion, and an undisclosed revenue split between the companies. Mesoblast will retain the responsibility to conduct certain Phase IIa trials and for commercial supply of the products in the alliance, while retaining the manufacturing rights. Signalling a wider interest in accessing Mesoblast's cutting edge technology platform and broad product offerings, Cephalon additionally made an equity investment in Mesoblast and purchased a 19.99% stake at $4.35/share, totalling approximately $240 million.
Mesoblast is using the proceeds obtained from the deal on further clinical and preclinical stem cell product development for a range of major indications, including type-2 diabetes, osteoporosis, inflammatory lung conditions, macular degeneration, and intervertebral disc repair.
Events subsequent to execution of this transaction, including the acquisition of Cephalon by Teva Pharmaceuticals and a strategic global manufacturing alliance between Mesoblast and biologics manufacturer Lonza, have only served to confirm and further reinforce the strategic nature and critical importance of this deal.”
Mesoblast Limited announced that its Phase 2 clinical trial for lumbar spinal fusion had met its safety and efficacy endpoints.
The results suggest that Mesoblast’s NeoFuse product comprising allogeneic Mesenchymal Precursor Cells (MPCs) is as effective for interbody lumbar fusion as the go ... more
Mesoblast Limited announced that it has reached agreement with the United States Food and Drug Administration (FDA) on the key elements of the company's first clinical trial using intravenous delivery of its proprietary allogeneic, or off-the-shelf, mesenchymal precursor cell (MPC) technolo ... more
Mesoblast Limited announced that a single intravenous injection of its proprietary adult stem cells resulted in significant lowering of blood sugar levels for up to eight weeks in a controlled, randomized preclinical trial in non-human primates with Type 2 diabetes. This was accompanied by ... more
Mesoblast Limited and its strategic alliance partner Cephalon Inc. were awarded the Licensing Executives Society (U.S.A. and Canada), Inc. 2011 Deals of Distinction™ Award. The award was conferred for the most compelling licensing and intellectual property-related deal in the life sciences ... more
Cephalon, Inc. announced that the company has received authorization from the Federal Institute for Drugs and Devices (BfArM) to market modafinil tablets in Germany for the treatment of moderate to severe chronic shift work sleep disorder with excessive sleepiness in patients working night ... more
CTI Technologies, Inc. (CTIT), a wholly-owned subsidiary of Cell Therapeutics, Inc. (CTI) announced that it has agreed to sell the TRISENOX brand to Cephalon, Inc. Under the terms of the agreement, Cephalon will pay to CTI and its affiliates an aggregate of approximately $70 million for TRI ... more